Vorapaxar NDA under Review for Prevention of Secondary Cardiovascular Events

Merck has announced that the FDA has accepted for review the New Drug Application (NDA) for its investigational anti-thrombotic, vorapaxar for the secondary prevention of cardiovascular events with a history of heart attack and no history of stroke or transient ischemic attack (TIA).

Vorapaxar is a novel, oral PAR-1 antagonist that inhibits thrombin-induced platelet activation.

For a list of currently FDA-approved medications including dosing for thromboembolic disorders, view the Therapy for Thromboembolic Disorders chart.

For more information call (800) 672-6372 or visit www.merck.com.